95 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26390077	42	Tactical Approaches to Interconverting GPCR Agonists and Antagonists.	University of Minnesota
25774991	23	N-benzoyl-1,5-benzothiazepine and its S-oxide as vasopressin receptor ligands: insight into the active stereochemistry around the seven-membered ring.	Teikyo University
25654260	49	Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.	F. Hoffmann-La Roche
25642985	45	Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.	University of Strasburg
24874785	333	New, potent, and selective peptidic oxytocin receptor agonists.	Ferring Research Institute
16250654	41	2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.	Glaxosmithkline
23312470	3	A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.	The College of New Jersey
23437772	35	Colloidal aggregation causes inhibition of G protein-coupled receptors.	University of North Carolina At Chapel Hill
21700453	56	Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.	Msd
20674355	58	Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.	Glaxosmithkline
19081251	38	Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist.	Glaxosmithkline
22984902	59	Selective fluorescent nonpeptidic antagonists for vasopressin V2 GPCR: application to ligand screening and oligomerization assays.	University of Strasburg
22239250	59	Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.	Glaxosmithkline
22425346	28	Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors.	Emory University
20104850	48	Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.	University of Strasburg
19800231	92	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.	Schering-Plough Research Institute
19095447	28	Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.	Glaxosmithkline
18032036	17	The discovery of GSK221149A: a potent and selective oxytocin antagonist.	Glaxosmithkline
17850055	18	Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.	Institute Genomics Functional (Igf)
16297621	17	Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.	Wyeth Research
16302826	129	Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.	Serono Pharmaceutical Research Institute
7241506	40	New analgesic drugs derived from phencyclidine.	TBA
15084136	96	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.	Medical College of Ohio
12036367	46	Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.	University of Montpellier
15149662	71	Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.	Johnson and Johnson Pharmaceutical Research and Development
15125926	88	Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.	Johnson & Johnson Pharmaceutical Research & Development
22249122	9	Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.	Lehigh University
21885275	65	Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.	Pfizer
21688787	295	New, potent, selective, and short-acting peptidic V1a receptor agonists.	Ferring Research Institute
21605973	69	Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties.	Abbott Laboratories
21601454	26	Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.	Msd
21428295	43	Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.	University of Montpellier
21353540	55	Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.	Msd
20550119	96	Oral oxytocin antagonists.	Drugmoldesign
20813948	63	Spiroindolones, a potent compound class for the treatment of malaria.	Swiss Tropical and Public Health Institute
20719508	26	Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists.	Ligand Pharmaceuticals
20471258	117	Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.	Pfizer
20189387	46	Identification of amide bioisosteres of triazole oxytocin antagonists.	Pfizer
19963374	68	Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.	Pfizer
19376698	16	Aryloxypyrazines as highly selective antagonists of Oxytocin.	Pfizer
19053774	56	New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.	Vantia
18778939	23	Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.	Pfizer
18639455	43	Design and optimization of potent, selective antagonists of Oxytocin.	Pfizer
17942308	62	Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.	Johnson & Johnson Pharmaceutical Research & Development
17855087	19	Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.	Wyeth Research
16392798	46	Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.	Columbia University College of Physicians and Surgeons
16153837	21	(4-Substituted-phenyl)-(5H-10,11-dihydro-pyrrolo [2,1-c][1,4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators.	Wyeth Research
15357997	22	Non-peptide oxytocin agonists.	Ferring Research
15125974	34	Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.	Johnson and Johnson Pharmaceutical Research and Development
14695824	68	Synthesis and structure-activity relationships of 5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine derivatives: novel arginine vasopressin antagonists.	Central Pharmaceutical Research Institute
14592501	33	2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists.	Johnson & Johnson Pharmaceutical Research & Development
12639574	21	Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists.	Johnson & Johnson Pharmaceutical Research & Development
12372506	41	Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity.	Johnson and Johnson Pharmaceutical Research and Development
12166952	6	Characterization of orally active nonpeptide vasopressin V(2) receptor agonist. Synthesis and biological evaluation of both the (5R)- and (5S)-enantioisomers of 2-[1-(2-Chloro-4-pyrrolidin-1-yl-benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin- 5-yl]-N-isopropylacetamide.	Otsuka Pharmaceutical
12036368	59	Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.	Yamanouchi Pharmaceutical
11087564	30	Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.	Otsuka Pharmaceutical
10782686	13	The design, synthesis and physical chemical properties of novel human vasopressin V2-receptor antagonists optimized for parenteral delivery.	Wyeth-Ayerst Research
10782666	46	The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepines.	Wyeth-Ayerst Research
31022340	101	Discovery of Potent, Selective, and Short-Acting Peptidic V	Ferring Research Institute
10406632	11	4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1]benzazepine derivatives as orally active arginine vasopressin receptor antagonists.	Wyeth-Ayerst Research
10340620	30	Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.	Merck Research Laboratories
10197974	22	Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.	University of Montpellier
31223461	56	Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier Penetration.	Shanghai Hengrui Pharmaceutical
9651149	54	5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.	Wyeth-Ayerst Research
31850759	24	Engineering a Potent, Long-Acting, and Periphery-Restricted Oxytocin Receptor Agonist with Anorexigenic and Body Weight Reducing Effects.	Calibr At The Scripps Research Institute
7473590	37	1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.	Merck Research Laboratories
3397986	14	Dicarbavasopressin antagonist analogues exhibit reduced in vivo agonist activity.	Smith Kline & French Laboratories
30199637	172	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.	Umr7200 Cnrs/Universit£
2522994	7	A minor modification of residue 1 in potent vasopressin antagonists dramatically reduces agonist activity.	Smith Kline & French Laboratories
2521519	26	Structure-activity relationships of novel vasopressin antagonists containing C-terminal diaminoalkanes and (aminoalkyl)guanidines.	Smith Kline & French Laboratories
29602673	49	Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.	Imperial College
28475329	18	Tolvaptan-Type Vasopressin Receptor Ligands: Important Role of Axial Chirality in the Active Form.	Teikyo University
26833890	18	Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease.	Yogi Vemana University
26469307	7	Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.	University of Leipzig
17252943	10	New natural cholinesterase inhibiting and calcium channel blocking quinoline alkaloids.	University of Karachi
15968818	10	Benzofuran- and furan-2-yl-(phenyl)-3-pyridylmethanols: synthesis and inhibition of P450 aromatase.	Cardiff University
12054506	26	The motilin pharmacophore in CHO cells expressing the human motilin receptor.	Katholieke Universiteit Leuven
12023553	5	Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.	University of North Carolina At Chapel Hill
16302795	36	Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.	Merck Frosst Centre For Therapeutic Research
11585446	6	Synthesis of novel, potent, diol-based HIV-1 protease inhibitors via intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal.	Stockholm University